Use of enoxaparin in patients with chronic kidney disease - Safety considerations

被引：8

作者：

Brophy, Donald F.

Sica, Domenic A.

机构：

[1] Virginia Commonwealth Univ, Dept Pharm, Richmond, VA 23298 USA

[2] Virginia Commonwealth Univ, Div Nephrol, Richmond, VA USA

[3] Virginia Commonwealth Univ, Sect Clin Pharmacol & Hypertens, Richmond, VA USA

来源：

DRUG SAFETY | 2007年 / 30卷 / 11期

关键词：

UNSTABLE ANGINA PATIENTS; UNFRACTIONATED HEPARIN; ESSENCE;

D O I：

10.2165/00002018-200730110-00001

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：991 / 994

页数：4

共 17 条

[1] Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial [J].

Antman, EM ;

McCabe, CH ;

Gurfinkel, EP ;

Turpie, AGG ;

Bernink, PJLM ;

Salein, D ;

de Luna, AB ;

Fox, K ;

Lablanche, JM ;

Radley, D ;

Premmereur, J ;

Braunwald, E .

CIRCULATION, 1999, 100 (15) :1593-1601

[2] Platelet dysfunction in renal failure [J].

Boccardo, P ;

Remuzzi, R ;

Galbusera, M .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2004, 30 (05) :579-589

[3] Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease [J].

Brophy, DF ;

Martin, EJ ;

Gehr, TWB ;

Best, AM ;

Paul, K ;

Carr, ME .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :372-376

[4] The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies [J].

Brophy, Donald F. ;

Carr, Marcus E., Jr. ;

Martin, Erika J. ;

Venitz, Jurgen ;

Gehr, Todd W. B. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (08) :887-894

[5] ENOXAPARIN - A REVIEW OF ITS PHARMACOLOGY AND CLINICAL-APPLICATIONS IN THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS [J].

BUCKLEY, MM ;

SORKIN, EM .

DRUGS, 1992, 44 (03) :465-497

[6] Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin [J].

Chow, SL ;

Zammit, K ;

West, K ;

Dannenhoffer, M ;

Lopez-Candales, A .

JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06) :586-590

[7] Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial [J].

Cohen, M ;

Demers, C ;

Gurfinkel, EP ;

Turpie, AGG ;

Fromell, GJ ;

Goodman, S ;

Langer, A ;

Califf, RM ;

Fox, KAA ;

Premmereur, J ;

Bigonzi, F .

AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (5B) :19L-24L

[8] Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials [J].

Collet, JP ;

Montalescot, G ;

Fine, E ;

Golmard, JL ;

Dalby, M ;

Choussat, R ;

Ankri, A ;

Dumaine, R ;

Lesty, C ;

Vignolles, N ;

Thomas, D .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (01) :8-14

[9] Enoxaparin in unstable angina patients with renal failure [J].

Collet, JP ;

Montalescot, G ;

Choussat, R ;

Lison, L ;

Ankri, A .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2001, 80 (01) :81-82

[10] Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin [J].

Gheno, G ;

Cinetto, L ;

Savarino, C ;

Vellar, S ;

Carraro, M ;

Randon, M .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (5-6) :373-377

← 1 2 →